Get the Stockscreener App
6.70
1.18%
-0.08
After Hours:
6.57
-0.13
-1.94%
Kala Bio Inc stock is traded at $6.70, with a volume of 5,795.
It is down -1.18% in the last 24 hours and up +24.07% over the past month.
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.
See More
Previous Close:
$6.78
Open:
$6.71
24h Volume:
5,795
Relative Volume:
0.37
Market Cap:
$31.53M
Revenue:
$5.75M
Net Income/Loss:
$-38.72M
P/E Ratio:
-95.71
EPS:
-0.07
Net Cash Flow:
$-31.04M
1W Performance:
-6.81%
1M Performance:
+24.07%
6M Performance:
-4.39%
1Y Performance:
-4.29%
1-Day Range:
$6.70
$6.89
1-Week Range:
$6.70
$7.10
52-Week Range:
$4.21
$10.97
Kala Bio Inc Stock (KALA) Company Profile
Name
Kala Bio Inc
Sector
Industry
Phone
781-996-5252
Address
1167 MASSACHUSETTS AVENUE, ARLINGTON, MA
Kala Bio Inc Stock (KALA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-30-22 | Downgrade | JP Morgan | Neutral → Underweight |
| Aug-06-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-14-20 | Downgrade | Jefferies | Buy → Hold |
| Jul-23-20 | Initiated | Northland Capital | Outperform |
| Jun-01-20 | Resumed | Oppenheimer | Outperform |
| May-27-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-09-20 | Upgrade | BofA/Merrill | Neutral → Buy |
| Dec-17-19 | Downgrade | BofA/Merrill | Buy → Neutral |
| Mar-14-19 | Initiated | Jefferies | Buy |
View All
Kala Bio Inc Stock (KALA) Latest News
Travis Kalanick | Biography, Uber, & Facts - Britannica
Persistent Corneal Epithelial Defects Pipeline 2024: Clinical - openPR
Persistent Epithelial Defect Market Size is Set for Rapid Growth - openPR
Sunrun (NASDAQ:RUN) Trading Down 5.8% on Insider Selling - Defense World
MPTI Stock Trades Near 52-Week High: Is It Still Worth Buying? - MSN
Here's What Makes Cabot Stock a Solid Choice Right Now - MSN
Here's Why Welltower Stock is an Apt Portfolio Pick for Now - MSN
Broadcom Stock Hits Buy Point On Product News Ahead Of Major Conference - MSN
KALA BIO (KALA) Moves to Strong Buy: Rationale Behind the Upgrade - Yahoo Finance
Dynatrace Shows Improved Relative Strength; Still Shy Of Benchmark - MSN
Brookdale Bets Big With $610M Acquisitions Amid Debt Refinancing - MSN
Toast, Inc. (TOST) is Attracting Investor Attention: Here is What You Should Know - MSN
Oppenheimer Initiates Coverage of Euronet Worldwide (EEFT) with Outperform Recommendation - MSN
Transparency-One’s Kala Hanson Named Recipient of 2024 Women in Supply Chain Award - Yahoo Finance
KALA BIO director resigns from board and committees By Investing.com - Investing.com Australia
KALA BIO director resigns from board and committees - Investing.com
Kala Pharmaceuticals Board Member Mark Blumenkranz Resigns - TipRanks
Kaival Brands’ (KAVL) Stock Surges After Merger Announcement with Delta Corp. - TipRanks
(KALA) Long Term Investment Analysis - Stock Traders Daily
Glazer Capital LLC Trims Holdings in Kairous Acquisition Corp. Limited (NASDAQ:KACL) - Defense World
Kaival Brands Innovations Group Inc. (NASDAQ:KAVL) Stock Makes a Big Move: But Why? - DRP Journal
Celebrities pour in appreciation for Vikky Varun's Kalapatthar - Cinema Express
Market Movers Monday: KAVL, PRSO, TGL, PNPNF, NVVE Surge on Breaking Developments - openPR
Market Movers to Watch: Black Diamond (Nasdaq: BDTX), Peraso Inc. (NASDAQ: PRSO), Kaival Brands (NASDAQ: KAVL) among others w/Key Announcements - Barchart
Kaival Brands Shares More Than Double on Delta Corp Holdings Merger - MarketWatch
What's Going On With Kaival Brands Stock Monday? - Benzinga
Kaival Brands Announces Strategic Merger with Delta Corp - TipRanks
Delta Corp Holdings Limited, a Fast Growing Asset-Light Logistics Company Enters into a Definitive Merger and Share Exchange Agreement with Kaival Brands Innovations Group, Inc. - StockTitan
Kayne Anderson Rudnick Investment Management LLC Purchases 15,512 Shares of Kadant Inc. (NYSE:KAI) - Defense World
ProShares Short S&P500 (NYSEARCA:SH) Hits New 12-Month Low at $11.02 - Defense World
Orange (NYSE:ORAN) Trading Down 1.7% - Defense World
Mutual of America Capital Management LLC Has $5.55 Million Stock Holdings in Rexford Industrial Realty, Inc. (NYSE:REXR) - Defense World
Mutual of America Capital Management LLC Reduces Holdings in Occidental Petroleum Co. (NYSE:OXY) - Defense World
Mutual of America Capital Management LLC Boosts Position in Electronic Arts Inc. (NASDAQ:EA) - Defense World
Rhumbline Advisers Raises Position in Reynolds Consumer Products Inc. (NASDAQ:REYN) - Defense World
Sensei Biotherapeutics names new financial chief - Investing.com India
Sensei Biotherapeutics names new financial chief By Investing.com - Investing.com South Africa
KALA BIO (KALA) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - MSN
KALA BIO (NASDAQ:KALA) Given “Outperform” Rating at Oppenheimer - Defense World
KALA (Kala Bio) Shares Outstanding (EOP) : 4.60 Mil (As of Jun. 2024) - GuruFocus.com
Financial Review: Lipella Pharmaceuticals (NASDAQ:LIPO) vs. Sagimet Biosciences (NASDAQ:SGMT) - Defense World
Analyzing Trevena (NASDAQ:TRVN) and KALA BIO (NASDAQ:KALA) - Defense World
Aptose Biosciences (NASDAQ:APTO) vs. ImmunityBio (NASDAQ:IBRX) Critical Review - Defense World
Analyzing GlycoMimetics (NASDAQ:GLYC) and Fulcrum Therapeutics (NASDAQ:FULC) - Defense World
KALA (Kala Bio) Profitability Rank : 1 (As of Jun. 2024) - GuruFocus.com
KALA (Kala Bio) Cash Flow from Investing : $9.66 Mil (TTM As of Jun. 2024) - GuruFocus.com
KALA BIO (NASDAQ:KALA) and UroGen Pharma (NASDAQ:URGN) Financial Contrast - Defense World
KALA BIO, Inc. (NASDAQ:KALA) Forecasted to Post Q3 2024 Earnings of ($2.15) Per Share - Defense World
KALA BIO to Present at H.C. Wainwright 4th Annual Ophthalmology Virtual Conference - GlobeNewswire
KALA BIO: Q2 Earnings Snapshot - San Antonio Express-News
Chondroitin Market Outlook: Revenue to Climb to USD 1.6 Billion by 2032, Driven by 2.8% CAGR | Future Market Insights Inc. - Future Market Insights
Kala Bio Inc Stock (KALA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Kala Bio Inc Stock (KALA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Kharabi Darius | CHIEF BUSINESS OFFICER |
Jun 26 '24 |
Sale |
4.75 |
5,158 |
24,500 |
59,728 |
| Reumuth Mary | CHIEF FINANCIAL OFFICER |
Jun 26 '24 |
Sale |
4.75 |
4,163 |
19,774 |
60,187 |
| Iwicki Mark T | CHIEF EXECUTIVE OFFICER |
Jun 26 '24 |
Sale |
4.75 |
15,168 |
72,048 |
263,755 |
| Brazzell Romulus K | SEE REMARKS |
Jun 26 '24 |
Sale |
4.75 |
5,489 |
26,073 |
83,982 |
| Bazemore Todd | SEE REMARKS |
May 31 '24 |
Sale |
6.09 |
2,093 |
12,746 |
87,693 |
| Kharabi Darius | CHIEF BUSINESS OFFICER |
May 31 '24 |
Sale |
6.09 |
231 |
1,407 |
64,886 |
| Reumuth Mary | CHIEF FINANCIAL OFFICER |
May 31 '24 |
Sale |
6.09 |
1,786 |
10,877 |
64,350 |
| Brazzell Romulus K | SEE REMARKS |
May 31 '24 |
Sale |
6.09 |
2,002 |
12,192 |
89,471 |
| Iwicki Mark T | CHIEF EXECUTIVE OFFICER |
May 31 '24 |
Sale |
6.09 |
7,392 |
45,017 |
278,923 |
| Trachtenberg Eric | SEE REMARKS |
Jan 04 '24 |
Sale |
6.74 |
1,227 |
8,270 |
68,066 |
2.02%
0.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):